Trastuzumab
- PDF / 172,131 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 63 Downloads / 136 Views
1
S
Cardiotoxicity: 2 case reports In a prospective, observational study (NCT01022086; from January 2010 to December 2013) involving 41 patients, two women [ages not stated] were described, who developed cardiotoxicity while receiving trastuzumab for breast cancer [not all duration of treatment to reaction onset stated]. The women, who had human epidermal growth factor receptor-2 positive invasive breast carcinoma, started receiving trastuzumab with a loading dose of 90-min infusion of 8 mg/kg followed by a maintenance dose of 30-min infusion of 6 mg/kg every 3 weeks scheduled up to 18 cycles for 12 months. One of the two women developed cardiotoxicity observed at 6 months multiple gated acquisition scan. Her left ventricular ejection fraction (LVEF) dropped from 67% (at baseline) to 45% (at 6 months). The other woman developed cardiotoxicity with an LVEF drop of
Data Loading...
